Search

AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to c

LONDON— Intraoperative radiotherapy given at the time of lumpectomy was found to be ‘non-inferior’ to the use of conventional post-operative whole breast external beam radiotherapy and had

AMSTERDAM—Screening men and women for colorectal cancer (CRC) with either fecal occult blood testing (FOBT) or endoscopy markedly lowered disease incidence and mortality in a study of screening patter

AMSTERDAM—Locoregional radiotherapy to the internal mammary and medial supraclavicular lymph nodes in women who had already been treated successfully for their breast cancer with standard regimens — i

AMSTERDAM—Long term survival — three to ten years — in nearly a quarter of patients with unresectable, metastatic or locally advanced melanoma treated with the cytotoxic T-lymphocyte antigen 4 (CTLA-4

IN THIS EDITION: Oral VEGF inhibitor, cediranib, extends life in refractory ovarian cancer Screening has halved colorectal cancer mortality in Europe Diabetes associated with increased risk of inciden

AMSTERDAM—A molecularly-directed approach to treatment decision-making with patients who have metastatic cancers of unknown primary site was being urged at the 2013 European Cancer Congress by researc

AMSTERDAM—The 2013 European Cancer Congress heard that new treatments could extend survival in patients with advanced and metastatic melanoma greatly beyond what has been the norm. Dr. Dirk Schadendor

AMSTERDAM—Postoperative radiotherapy to the internal mammary and supraclavicular lymph nodes in women whose breast cancer has been successfully treated and are at low risk of relapse could save lives

AMSTERDAM—People with diabetes have an increased risk of developing and dying from certain cancers, according to a meta-analysis with two million patients reported at the 2013 European Cancer Congress

AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a myocardial infarction was scrutinised in a debate a

AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in type II diabetes but has failed to show a benefit in